Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort
Completed · Early Phase 1 · Has a placebo group
Conditions studied: Health Adult Subjects, Healthy Participants
In brief
The goal of this 5 day interventional study was to investigate the effects on multiple biological molecules (multi-omics) of Bryleos's commercially available oral LathMized™ Nicotinamide adenine dinucleotide (LNAD+) supplement in healthy adults aged 45-75 years. The main question to be answered was whether LNAD+ supplementation is associated with change in biological markers relevant to subjects' health. Also, the study determined whether this oral NAD+ formulation raised NAD+ levels including inside blood cells, after the 5 day treatment period, measured on post-treatment Day 1 (Day 6). Thus, the study compared NAD+ levels and impact on biological markers in the LNAD+ arm versus control placebo arm. Safety in this population was assessed using clinical laboratory tests, daily self-reporting of symptoms, and data from a wearable device.
Key facts
- Study ID
- NCT07336836
- Run by
- BioNADrx Holdings, Inc. Bryleos
- People needed
- 60
- Starts
- 2022-02-23
- Expected to finish
- 2022-06-04
- Last updated by the study team
- 2026-01-13
Who can join
Age: 45 and older, up to 75. Sex: any. Healthy volunteers: accepted.
You may not qualify if…
- Body Mass Index (BMI) > 35 kg/m2;
- Current chronic or acute infectious diseases (e.g., hepatitis, influenza, HIV, Lyme; COVID-19 within the past two months);
- Recent SARS-CoV-2 vaccine administration (within two weeks);
- Current use of NAD+ supplements and precursors;
- Use of systemic anti-inflammatory medications (excluding NSAIDs and acetaminophen), immunosuppressants;
- Current cancer or hematologic conditions and/or cancer treatment (radiation, chemotherapy);
- Type I juvenile or Type 2 diabetes mellitus;
- Autoimmune disorders (multiple sclerosis, lupus, rheumatoid arthritis, psoriasis);
- Inflammatory bowel disease (ulcerative colitis, Crohn's disease);
- Current pregnancy;
- Current substance abuse, including alcohol, but excluding nicotine and prescription medications (e.g., physician-prescribed stimulants, opiates);
- Members of the same household.
Where it is running
- ISB Bioanalytica, Inc. — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.